2025/04/30
TaiMed Biologics Signed CDMO Service Agreement with U.S. Client, Adding Growth Momentum to Operations
2025/04/09
On April 2, 2025, the United States announced the implementation of a reciprocal tariff policy on countries and regions worldwide. This has no significant impact on the company's operations.
2025/04/02
Macau Pharmaceutical Administration Bureau Approves TaiMed Bologics’ Trogarzo as the First and Only Monoclonal Antibody for the Treatment of HIV
2025/04/02
Dr. Jimmy Chang, CEO of TaiMed Biologics interviewed by BioWorld
2025/03/13
TaiMed marketing partner, Theratechnologies Inc announcement of presentation from Virologic Suppression Data from the PROMISE-US Trial of Ibalizumab at CROI
2025/03/12
TaiMed Biologics to Present Late-Breaking Phase IIa Data at CROI 2025 on Long-Acting TMB-365/TMB-380 Regimen for HIV Maintenance Therapy.
2025/03/06
TaiMed Biologics and Helios Pharmaceutical Company Limited Partner to Commercialize Trogarzo® in Vietnam
2025/03/05
TaiMed Biologics Invests in Marigold Therapeutics to Advance Antibody-Drug Conjugate (ADC) Drug Development
2025/02/24
TaiMed Biologics and Slim Pharmaceuticals Partner to Commercialize Trogarzo® In Sri Lanka
2025/01/21
TaiMed Announces Phase 2a Clinical Study Results of Long-Acting TMB-365/TMB-380 Combination Therapy for HIV Have Been Accepted to Present at CROI 2025 Annual Conference
2025/01/08
TaiMed Biologics Announces its Long-Acting TMB-365/380 Monoclonal Antibody Combination HIV Therapy Meets All Primary Endpoints in Phase 2a Clinical Study